John Kenneth Jenkins - Net Worth and Insider Trading

John Kenneth Jenkins Net Worth

The estimated net worth of John Kenneth Jenkins is at least $1,130 dollars as of 2024-04-28. John Kenneth Jenkins is the Director of Corbus Pharmaceuticals Holdings Inc and owns about 33 shares of Corbus Pharmaceuticals Holdings Inc (CRBP) stock worth over $1,130. Details can be seen in John Kenneth Jenkins's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John Kenneth Jenkins has not made any transactions after 2019-03-15 and currently still holds the listed stock(s).

Transaction Summary of John Kenneth Jenkins

To

John Kenneth Jenkins Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Kenneth Jenkins owns 2 companies in total, including Provention Bio Inc (PRVB) , and Corbus Pharmaceuticals Holdings Inc (CRBP) .

Click here to see the complete history of John Kenneth Jenkins’s form 4 insider trades.

Insider Ownership Summary of John Kenneth Jenkins

Ticker Comapny Transaction Date Type of Owner
PRVB Provention Bio Inc 2020-08-10 director
CRBP Corbus Pharmaceuticals Holdings Inc 2019-03-15 director

John Kenneth Jenkins Latest Holdings Summary

John Kenneth Jenkins currently owns a total of 1 stock. John Kenneth Jenkins owns 33 shares of Corbus Pharmaceuticals Holdings Inc (CRBP) as of March 15, 2019, with a value of $1,130.

Latest Holdings of John Kenneth Jenkins

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CRBP Corbus Pharmaceuticals Holdings Inc 2019-03-15 33 34.25 1,130

Holding Weightings of John Kenneth Jenkins


John Kenneth Jenkins Form 4 Trading Tracker

According to the SEC Form 4 filings, John Kenneth Jenkins has made a total of 0 transactions in Corbus Pharmaceuticals Holdings Inc (CRBP) over the past 5 years. The most-recent trade in Corbus Pharmaceuticals Holdings Inc is the acquisition of 33 shares on March 15, 2019, which cost John Kenneth Jenkins around $6,980.

Insider Trading History of John Kenneth Jenkins

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John Kenneth Jenkins Trading Performance

GuruFocus tracks the stock performance after each of John Kenneth Jenkins's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Kenneth Jenkins is 2.24%. GuruFocus also compares John Kenneth Jenkins's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Kenneth Jenkins within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John Kenneth Jenkins's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John Kenneth Jenkins

Average Return

-39.25%

Average return per transaction

Outperforming Transactions

0%

0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 6.87 2.24 -14.33 -39.25 -41.75 -61.54
Relative Return to S&P 500(%) 3.93 -0.05 -20.88 -35.3 -60.31 -76.26

John Kenneth Jenkins Ownership Network

Ownership Network List of John Kenneth Jenkins

No Data

Ownership Network Relation of John Kenneth Jenkins


John Kenneth Jenkins Owned Company Details

What does Provention Bio Inc do?

Who are the key executives at Provention Bio Inc?

John Kenneth Jenkins is the director of Provention Bio Inc. Other key executives at Provention Bio Inc include 10 percent owner Sessa Capital (master), L.p. , director & 10 percent owner & Chief Scientific Officer Francisco Leon , and director & 10 percent owner & President and CEO Ashleigh Palmer .

Provention Bio Inc (PRVB) Insider Trades Summary

Over the past 18 months, John Kenneth Jenkins made no insider transaction in Provention Bio Inc (PRVB). Other recent insider transactions involving Provention Bio Inc (PRVB) include a net sale of 299,617 shares made by Francisco Leon , a net sale of 5,190,549 shares made by Sessa Capital (master), L.p. , and a net sale of 100,000 shares made by Ashleigh Palmer .

In summary, during the past 3 months, insiders sold 0 shares of Provention Bio Inc (PRVB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 5,594,666 shares of Provention Bio Inc (PRVB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 5,594,666 shares.

Provention Bio Inc (PRVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Provention Bio Inc Insider Transactions

No Available Data

John Kenneth Jenkins Mailing Address

Above is the net worth, insider trading, and ownership report for John Kenneth Jenkins. You might contact John Kenneth Jenkins via mailing address: C/o Corbus Pharmaceuticals Holdings, Inc, 100 River Ridge Drive, Norwood Ma 02062.

Discussions on John Kenneth Jenkins

No discussions yet.